secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2026-08-28T20:05:51+00:00
Accession:  0001193125-26-374328
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 1.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo sells ST-920 Fabry gene therapy to PTC for $111M cash plus $100M milestones in Chapter 11
--------------------------------------------------------------------------------

- Sangamo filed Chapter 11 on June 23, 2026; PTC won auction for ST-920 assets.
- Deal: $111M cash at closing plus up to $100M milestones; $80M on FDA accelerated approval, $20M on full approval.
- Bankruptcy Court hearing to approve sale scheduled for September 10, 2026; closing by October 15, 2026.
- ST-920 is AAV gene therapy for Fabry disease; PTC assumes specified liabilities.
- Stock delisted from Nasdaq May 5, 2026; now trades OTC as SGMOQ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000119312526374328/0001193125-26-374328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000119312526374328/d116527d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-374328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer